COVID-19 Vaccines Market Size, Trends and Analysis by Disease Overview, Epidemiology, Unmet Needs and Opportunities, Therapeutic Landscape, Pipeline Assessment, Clinical Trial Strategies and Forecast to 2026

The report provides an in-depth assessment of the COVID-19 market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market outlook.

COVID-19 is a disease caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in the city of Wuhan, China in December 2019. The initial outbreak is thought to have originated in an animal market and spread rapidly throughout the city and region. By late March 2020, global COVID-19 cases surpassed 100,000, and the WHO officially declared the outbreak a global pandemic. To date, more than 767 million confirmed COVID-19 cases have been documented around the globe, along with over 6.9 million COVID-19-associated deaths.

The virus spreads mainly through respiratory droplets released by an infected person to people in close contact. Symptoms can range from mild to severe and may include fever, chills, cough, sore throat, shortness of breath, fatigue, muscle aches, headache, congestion, nausea or vomiting, diarrhea, confusion, and loss of taste or smell. A wide range of other less common symptoms have also been reported. Complications of COVID-19 include acute respiratory distress syndrome (ARDS), pneumonia, blood clots, acute kidney injury (AKI), and multi-organ failure. COVID-19 has also been linked to various long-term symptoms that may last for weeks, months, or years post infection. This condition is referred to as “long COVID”. Common symptoms include fatigue, headaches, “brain fog”, changes in smell and/or taste, cough, difficulty sleeping, and anxiety. Research is currently ongoing to better understand the condition and how to approach treatment.

The development of COVID-19 vaccines occurred at an unprecedented speed. The first mRNA Phase III vaccine efficacy data was presented by Pfizer/BioNTech and Moderna seven months after Phase I clinical trial initiation, with these becoming the first of the COVID-19 vaccines to gain authorization for use by December 2020. The rapid development and authorization of mRNA-based vaccines in response to the COVID-19 pandemic marks a critical milestone for scientific research and the vaccine space.

Globally, over 5 billion individuals are now fully vaccinated with a primary vaccination series, with over 13.4 billion cumulative vaccine doses administered.

Key Highlights

• Report deliverables include a Pdf and an Excel-based forecast model
• Forecast includes the 7 major markets (7MM)
• Forecast covers the period 2021-2026

Scope

• Overview of Coronavirus disease 2019 (COVID-19) including classification of SARS-CoV-2, etiology, pathophysiology, and epidemiology of COVID-19 and timeline of COVID-19 outbreak and vaccine development
• Current treatment options including product profiles for COVID-19 vaccines authorized in the 7MM
• Analysis of unmet needs and R&A strategies within the COVID-19 market
• Pipeline analysis including product profiles for leading vaccine candidates in the 7MM
• COVID-19 vaccines market outlook including revenue breakdown by market in 2021 and 2026, revenue breakdown by vaccine type in 2021 and 2026, revenues for leading vaccine products in 2021 and 2026

Reasons to Buy

• Understand the trends shaping and driving the COVID-19 vaccines market
• Identify the innovative technologies and key players leading the COVID-19 vaccines field
• Recognize gaps and areas of unmet need within the COVID-19 vaccines market
• Determine the current and future outlook for COVID-19 vaccines according to key opinion leaders (KOLs)
• Track COVID-19 vaccine sales from 2021-2026